Bausch + Lomb, a leading global eye health company, announced today that it has expanded its specialty lens business with the addition of Alden Optical Laboratories, Inc., a privately-held company that manufactures premium specialty and custom soft and gas permeable (GP) contact lenses. The addition of Alden demonstrates Bausch + Lomb’s commitment to addressing ocular conditions such as myopia, and other serious visual challenges including irregular corneas, by providing a comprehensive portfolio of specialty and custom contact lenses to meet the needs of eye care providers (ECPs) and their patients. The acquisition of Alden was made through an affiliate of Bausch + Lomb.

The expanded business, known as Bausch + Lomb Specialty Vision Products (formerly known as Advanced Vision Products, no affiliation with Advanced Vision Technologies, based in Lakewood, CO), is dedicated to delivering innovative products, education, and training for ECPs in the specialty and custom contact lens space.

“We are excited to bring Alden’s strong heritage of a diverse and extensive portfolio of premium specialty lenses, including the Zenlens™, a mini-scleral lens, and the NovaKone® lenses for keratoconus, into our Vision Care business as part of Bausch + Lomb Specialty Vision Products,” said Mark McKenna, senior vice president and general manager, Contact Lenses, Bausch + Lomb. “Our companies have a shared vision in serving the needs of practitioners and patients with innovative and high-quality products and exceptional service. Together, we look forward to delivering the benefits of this combination and addressing the vision needs of patients with challenging visual conditions under the Bausch + Lomb Specialty Vision Products division.”

David Bland, director of custom lens business, has worked extensively on Bausch + Lomb’s Boston® side of the business since 1988 and will lead the Specialty Vision Products business under McKenna.

Bausch + Lomb has provided innovative solutions, materials and support to the gas permeable community for decades through its Boston® brand of products. The addition of Alden, coupled with Bausch + Lomb’s other R&D initiatives, will further support and fulfill the growing needs of the GP market by providing ECPs finished contact lenses for serious optical conditions such as keratoconus, Pellucid Marginal Degeneration (PMD), post-refractive surgery, and certain ocular surface diseases.

“We’re pleased that Alden’s portfolio of products has been recognized as exceptional by Bausch + Lomb,” said Charley Creighton, chief executive officer, Alden Optical Laboratories, Inc. “Alden is a natural complement to Bausch + Lomb’s decades of leadership in its line of high quality Boston® materials and solutions, especially with Alden receiving full ISO 13485 certification in December confirming our innovative products and services conform to the world-wide standard for quality. We are confident that under their stewardship, the Alden brands will continue to stand for excellence and innovation in eye health.”

Creighton, and Tom Shone, president of Alden Optical Laboratories, Inc., will remain with Bausch + Lomb serving as senior consultants to McKenna and play an integral role in developing the finished lens portion of the business.

“I am pleased that Bausch + Lomb is helping to address the visual needs of patients who require specialized and custom lenses, as there are many who can benefit from what these lenses can offer,” said Lynette K. Johns, OD, clinical attending at the New England Eye Commonwealth, and clinical and educational consultant to Bausch + Lomb Specialty Vision Products. “Often, these patients have debilitating ocular conditions, and it can be very challenging to treat and fit their eyes. As a clinician, it is very important to have access to a wide variety of lens options to effectively manage these unique patients. As an educator, students should also be exposed to a large repertoire of options. All of these efforts contribute to improving the quality of life of our patients.”

As part of the Specialty Vision Products business, Bausch + Lomb will provide substantial investment to expand the training and education programs offered to ECPs and students, and other key programs and initiatives. To support ECP’s custom lens and lens care needs, a highly skilled team of sales, fitting consultants, and specialty lens trainers will be available to provide the latest information on products, training events, and fitting tools and resources available via workshops, webinars, and online tools, to help ECPs meet the specific needs of their patients.

“We are committed to supporting the specialty lens category, to providing education and training, and to investing in research to bring new advancements to market. With the addition of Alden and partnership with the eye care community, Bausch + Lomb’s Specialty Vision Products business will be able to bring more specialty lenses to more patients, and ensure that together, we are doing our best to help the eye care community provide excellence in vision care,” said McKenna.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

Forward-looking Statements
This press release may contain forward-looking statements, including, but not limited to, statements regarding the continuity and management of Bausch + Lomb’s business operations. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company’s most recent annual or quarterly report and detailed from time to time in Valeant Pharmaceuticals International, Inc.’s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.